These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 35908290

  • 1. Radioactive Iodine Therapy Does not Improve Cancer-specific Survival in Hürthle Cell Carcinoma of the Thyroid.
    Wang X, Zheng X, Zhu J, Li Z, Wei T.
    J Clin Endocrinol Metab; 2022 Nov 23; 107(11):3144-3151. PubMed ID: 35908290
    [Abstract] [Full Text] [Related]

  • 2. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis.
    Guo H, Zhang N, Hu Y, Zhang F, Huang T, Shen N.
    Front Endocrinol (Lausanne); 2023 Nov 23; 14():1158581. PubMed ID: 37664843
    [Abstract] [Full Text] [Related]

  • 3. Radioactive iodine therapy may not improve disease-specific survival in follicular variant papillary thyroid cancer without distant metastasis: A propensity score-matched analysis.
    Wang X, Zheng X, Zhu J, Li Z, Wei T.
    Head Neck; 2021 Jun 23; 43(6):1730-1738. PubMed ID: 33559196
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of adjuvant radioactive iodine therapy on survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma).
    Yang Q, Zhao Z, Zhong G, Jin A, Yu K.
    PeerJ; 2019 Jun 23; 7():e7458. PubMed ID: 31523497
    [Abstract] [Full Text] [Related]

  • 6. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
    Zhao H, Gong Y.
    Front Endocrinol (Lausanne); 2022 Jun 23; 13():960682. PubMed ID: 36034423
    [Abstract] [Full Text] [Related]

  • 7. Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer.
    Tang T, Zhi J, Zhang W, Hu L, Ruan X, Chen X, Wang Z, Zheng X, Gao M.
    J Healthc Eng; 2022 Jun 23; 2022():4348396. PubMed ID: 35178227
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
    Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI.
    Cancer; 2003 Mar 01; 97(5):1186-94. PubMed ID: 12599224
    [Abstract] [Full Text] [Related]

  • 9. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
    Sun Y, Gong J, Guo B, Shang J, Cheng Y, Xu H.
    Oral Oncol; 2018 Dec 01; 87():152-157. PubMed ID: 30527231
    [Abstract] [Full Text] [Related]

  • 10. Radioactive Iodine Treatment Is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma.
    Jillard CL, Youngwirth L, Scheri RP, Roman S, Sosa JA.
    Thyroid; 2016 Jul 01; 26(7):959-64. PubMed ID: 27150319
    [Abstract] [Full Text] [Related]

  • 11. Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma.
    Wang J, Mao Y, Li L, Liang J, Huang H, Lin W, Chen G, Wen J.
    Endocrine; 2024 Nov 01; 86(2):664-671. PubMed ID: 38809346
    [Abstract] [Full Text] [Related]

  • 12. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P, Wang CH, Abadin SS, Block R, Raghavan V, Moo-Young TA, Prinz RA, Winchester DJ.
    Endocr Pract; 2016 Jul 01; 22(7):822-31. PubMed ID: 27018620
    [Abstract] [Full Text] [Related]

  • 13. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
    Lin B, Qiang W, Wenqi Z, Tianyu Y, Lina Z, Bin J.
    Nucl Med Commun; 2017 Dec 01; 38(12):1036-1040. PubMed ID: 28953211
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS, Zanella AB, Dora JM, Maia AL.
    Thyroid; 2016 Nov 01; 26(11):1623-1629. PubMed ID: 27549175
    [Abstract] [Full Text] [Related]

  • 17. Clinicopathological features and outcomes after radioactive iodine treatment of oncocytic well-differentiated thyroid carcinomas.
    Amouri W, Charfeddine S, Charfi S, Jardak I, Boudawara T, Guermazi F.
    Nucl Med Commun; 2019 Sep 01; 40(9):888-893. PubMed ID: 31343615
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
    Liu X, Fan Y, Liu Y, He X, Zheng X, Tan J, Jia Q, Meng Z.
    Updates Surg; 2020 Sep 01; 72(3):871-884. PubMed ID: 32342347
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.